Vanguard Group
CBAY

Vanguard Group’s Cymabay Therapeutics CBAY Stock Holding History

Vanguard Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,306,149
Closed -$149M – 4500
2023
Q4 		$149M Buy
6,306,149
+558,562
+10% +$9.95M ﹤0.01% 1660
2023
Q3 		$85.7M Buy
5,747,587
+598,707
+12% +$7.94M ﹤0.01% 1886
2023
Q2 		$56.4M Buy
5,148,880
+699,272
+16% +$6.51M ﹤0.01% 2132
2023
Q1 		$38.8M Buy
4,449,608
+774,310
+21% +$6.2M ﹤0.01% 2290
2022
Q4 		$23M Buy
3,675,298
+10,236
+0.3% +$38.9K ﹤0.01% 2553
2022
Q3 		$12.8M Buy
3,665,062
+108,020
+3% +$388K ﹤0.01% 2830
2022
Q2 		$10.5M Sell
3,557,042
-285,334
-7% -$682K ﹤0.01% 2968
2022
Q1 		$11.9M Buy
3,842,376
+53,919
+1% +$170K ﹤0.01% 3055
2021
Q4 		$12.8M Buy
3,788,457
+443,149
+13% +$1.68M ﹤0.01% 3089
2021
Q3 		$12.2M Buy
3,345,308
+18,526
+0.6% +$73K ﹤0.01% 3132
2021
Q2 		$14.5M Sell
3,326,782
-367,636
-10% -$1.63M ﹤0.01% 3014
2021
Q1 		$16.8M Buy
3,694,418
+267,407
+8% +$1.44M ﹤0.01% 2876
2020
Q4 		$19.7M Buy
3,427,011
+53,892
+2% +$408K ﹤0.01% 2641
2020
Q3 		$24.4M Sell
3,373,119
-7,631
-0.2% -$40.8K ﹤0.01% 2355
2020
Q2 		$11.8M Sell
3,380,750
-309,090
-8% -$892K ﹤0.01% 2682
2020
Q1 		$5.46M Sell
3,689,840
-1,485
-0% -$2.49K ﹤0.01% 2941
2019
Q4 		$7.24M Buy
3,691,325
+13,931
+0.4% +$52.3K ﹤0.01% 3010
2019
Q3 		$18.8M Buy
3,677,394
+117,519
+3% +$711K ﹤0.01% 2517
2019
Q2 		$25.5M Buy
3,559,875
+226,906
+7% +$2.57M ﹤0.01% 2391
2019
Q1 		$44.3M Buy
3,332,969
+397,479
+14% +$4.23M ﹤0.01% 2152
2018
Q4 		$23.1M Buy
2,935,490
+146,302
+5% +$1.39M ﹤0.01% 2386
2018
Q3 		$30.9M Buy
2,789,188
+109,989
+4% +$1.37M ﹤0.01% 2371
2018
Q2 		$36M Buy
2,679,199
+140,285
+6% +$1.76M ﹤0.01% 2299
2018
Q1 		$33M Buy
2,538,914
+759,607
+43% +$9.44M ﹤0.01% 2289
2017
Q4 		$16.4M Buy
1,779,307
+238,105
+15% +$2.03M ﹤0.01% 2580
2017
Q3 		$12.4M Buy
1,541,202
+549,569
+55% +$3.72M ﹤0.01% 2709
2017
Q2 		$5.71M Buy
991,633
+170,126
+21% +$724K ﹤0.01% 3038
2017
Q1 		$3.53M Buy
821,507
+293,823
+56% +$843K ﹤0.01% 3191
2016
Q4 		$913K Sell
527,684
-87,021
-14% -$154K ﹤0.01% 3586
2016
Q3 		$1.19M Buy
614,705
+2,456
+0.4% +$4.88K ﹤0.01% 3535
2016
Q2 		$1.06M Buy
612,249
+62,896
+11% +$130K ﹤0.01% 3592
2016
Q1 		$742K Buy
549,353
+50,627
+10% +$62.7K ﹤0.01% 3679
2015
Q4 		$843K Buy
498,726
+70,819
+17% +$115K ﹤0.01% 3676
2015
Q3 		$830K Buy
427,907
+95,600
+29% +$260K ﹤0.01% 3690
2015
Q2 		$894K Buy
332,307
+14,260
+4% +$58.6K ﹤0.01% 3690
2015
Q1 		$2.2M Buy
318,047
+32,200
+11% +$309K ﹤0.01% 3366
2014
Q4 		$2.81M Buy
285,847
+3,400
+1% +$27.3K ﹤0.01% 3155
2014
Q3 		$1.93M Buy
+282,447
New +$1.74M ﹤0.01% 3278

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Group's CBAY Position: Q1 2024 in Review

Vanguard Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 6,306,149 shares — an estimated $149M sold.

Vanguard Group first reported a position in CBAY in Q3 2014 and held it in 38 quarters. The position peaked at $149M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Vanguard Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 6,306,149 Cymabay Therapeutics shares in Q1 2024, an estimated $149M.
  • Vanguard Group first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 38 quarters.
  • Vanguard Group's Cymabay Therapeutics position peaked at $149M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.